Adocia SA (FRA:A89)

Market Cap	82.76M +17.3%
Revenue (ttm)	3.85M -68.3%
Net Income	-16.59M
EPS	-0.93
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.934
Previous Close	3.978
Day's Range	3.934 - 3.934
52-Week Range	3.590 - 11.400
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 24, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 73
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: A89

Financial Performance

In 2025, Adocia's revenue was 3.85 million, a decrease of -68.26% compared to the previous year's 12.12 million. Losses were -16.59 million, 78.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error